List of Radiopharmaceuticals/Radiotherapies Companies with Phase 1 Active Clinical Trial - 14

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Nasal breathing is a very important function of human life and any obstruction in the nasal airway also known as a congested or blocked nose, can dramatically impact the quality of life.The VIVAER treatment, performed in a doctor’s office, is a non-invasive procedure without any incisions. The patient'snasal valve area is gently reshaped using low-temperature radiofrequency energy with lasting results.

Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care.

At Creo Medical we are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. Our integrated electrosurgery unit delivers Bipolar Radiofrequency for precise dissection and resection and Microwave energy for controlled ablation and coagulation. This technology sets a new standard for Endoscopic Submucosal Dissection with our new Speedboat RS2 instrument: the Bipolar Radiofrequency cut allows precise dissection and the microwave coagulation provides controlled haemostasis while the protective hull reduces the risk of muscle damage and the integrated injection needle helps to maintain submucosal lift without instrument changes.

Cynosure is a leader in the medical devices industry specializing in aesthetic medicine and cosmetic procedures.

Duke Street Bio is focused on exploiting tumour genetic vulnerabilities and harnessing the natural power of the body’s immune system to fight cancer.

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China.

Monopar Therapeutics is a clinical­-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR­101, a late-­stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR­202, an early-stage camsirubicin analog for various cancers.

Nanobiotix has been pioneering nanomedicine for more than 17 years to bring a different approach to medicine. Our therapeutic technologies are not based on biology or chemistry – they are based on physical principles at nanoscale. This paradigm shift has allowed us to discover novel approaches to improving treatment outcomes. Our company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. With this approach, our ambition is to benefit millions of patients who receive radiation therapy by improving the efficiency of radiation in tumor cells without increasing the dose received by surrounding healthy tissues. We believe that radiotherapy combined with NBTXR3 can become a new standard of care in the treatment of cancer. By viewing the human body through the lens of physics a new realm of possibilities has emerged.

Primo is a radiopharmaceutical company based in Taiwan. In order to facilitate precision healthcare with molecular imaging in Taiwan, Primo was founded by Prof. Ya-Yao Huang and Dr. Joe Yeh in 2021 with many-year radiopharmaceutical discovery/development experience in Taiwan, especially about clinical introduction and IND submission of new radiopharmaceuticals. For several years now, our company has been focused on the one-stop clinical development of radiotheranostics in Taiwan, especially form pre-clinical studies, clinical network and regulatory filling to manufacturing , commercialization and distribution activities in Taiwan.

Building out a pipeline of small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) to treat a range of cancers.

The company uses biology-guided radiotherapy to detect and respond to signals emitted from cancer cells, and use them to guide treatment.

SmartNuclide Biopharma is a biopharmaceutical company that focuses on discovering and developing innovative biologics used in nuclear medicine, with a world-leading research and development technology platform for domain antibody-radiopharmaceuticals.

Tagworks Pharmaceuticals is a precision oncology company using our proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors by targeting clinically validated tumor markers that so far have remained out of reach of current therapies. Our lead program, TGW101, is an antibody-drug conjugate (ADC) targeting TAG72, a non-internalizing protein found on the surface of many solid tumor cells. We are developing a pipeline of novel cancer treatments leveraging our Click-to-Release technology in a range of therapeutic modalities, including ADCs and targeted radionuclide therapies. We are headquartered in the Netherlands with operations in the U.S. For more information, visit us at www.tagworkspharma.com.